Digital health companies must commit to the highest standards – STAT
The stakes are too high for digital health companies to rely on the standards used by other tech companies for backing product claims.
The stakes are too high for digital health companies to rely on the standards used by other tech companies for backing product claims.
This week in health policy and politics news: What RFK Jr. could mean for addiction treatment and analyzing a bill to take on PBMs.
Today’s health news includes the health care critics featured in the UnitedHealthcare suspect’s manifesto and the global healthspan-lifespan gap.
The efficacy data could help cushion Ibrance’s losses of market share to Kisqali, a similar drug from Novartis.
Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year
Report: Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815 million in 2023.
Why Arcellx won the battle of BCMA CAR-T therapies against Legend Biotech.
Stoke Therapeutics is nearing FDA sign-off on a groundbreaking Phase 3 clinical trial for its experimental drug for Dravet syndrome.
As health insurers use AI to deny more claims, startups are turning to AI to make it easier to appeal denials, which often go uncontested.
Presenting the five stages of AI grief (techbio’s version), from Tessel Bio’s @NTallapragada.
Akshara Ramasamy will soon begin medical school in Texas — but the state’s new requirement to ask hospital patients about immigration status worries her.